![Harvey N. Masonson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Harvey N.
Masonson held several positions in the pharmaceutical industry, including Assistant Director-Clinical Safety at Bristol Myers Squibb Co., Director-Clinical Research at Sanofi-Synthelabo, Inc., Vice President-Clinical Development & Drug Safety at (OSI).
Eyetech, and Senior Vice President-Clinical Development at IVERIC bio, Inc. He also served as Vice President-Clinical Development at Gensight Biologics SA from 2018 to 2019.
Masonson earned a doctorate degree from the Icahn School of Medicine at Mount Sinai.
Anciens postes connus de Harvey N. Masonson
| Sociétés | Poste | Fin |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Directeur Technique/Scientifique/R&D | 01/01/2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
(OSI) Eyetech
 (OSI) Eyetech Medical SpecialtiesHealth Technology Provides medical services | Corporate Officer/Principal | - |
Sanofi-Synthelabo, Inc. | Directeur Technique/Scientifique/R&D | - |
| IVERIC BIO, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Harvey N. Masonson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
2
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology Provides medical services | Health Technology |
Icahn School of Medicine at Mount Sinai
 Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IVERIC bio, Inc.
 IVERIC bio, Inc. BiotechnologyHealth Technology Operates as a science-driven biopharmaceutical company that develops novel treatments for retinal diseases | Health Technology |
Sanofi-Synthelabo, Inc. | Health Technology |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
Choisissez Zonebourse 
